Brain Metastasis Clinical Trial
Official title:
Studies of Methionine-PET and PBR28-PET in Brain Metastases to Differentiate Tumor Recurrence and Radiation Necrosis Following Stereotactic Radiosurgery
NCT number | NCT02433171 |
Other study ID # | 1401013294 |
Secondary ID | |
Status | Terminated |
Phase | |
First received | |
Last updated | |
Start date | January 2015 |
Est. completion date | June 27, 2017 |
Verified date | May 2019 |
Source | Yale University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The goal of this protocol is to evaluate the potential of PET imaging of amino acid transport and microglial activation to improve the differentiation of tumor recurrence and radiation necrosis in patients with brain metastases after treatment with stereotactic radiosurgery (SRS) who have re-growing lesions. These state-of-the-art imaging tools will be used in combination with standard magnetic resonance imaging (MRI), MR spectroscopy (MRS) and FDG-PET (fluorodeoxyglucose).
Status | Terminated |
Enrollment | 8 |
Est. completion date | June 27, 2017 |
Est. primary completion date | June 27, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Patients over 18 years with brain metastases from melanoma or non-small cell lung cancer - Patients must have had SRS and regrowth in at least one lesion > 0.5 cm in greatest dimension and fall into one of two categories: a) patient is deemed clinically appropriate for surgical intervention (biopsy or craniotomy) OR b) patient is asymptomatic and has a life expectancy of > 6 months so that serial follow-up imaging is appropriate - Willingness to participate in imaging studies - Able to give informed consent Exclusion Criteria: - Subjects with history of prior radiation exposure for research purposes within the past year, such that participation in this study would place them over the FDA limits for annual radiation exposure. This guideline is an effective dose of 5 rem received per year. - Subjects who are pregnant or currently breastfeeding - Women of child-bearing age who are sexually active, unless they agree to two forms of contraception, and have a negative urine pregnancy test at screening and on the days of the PET imaging - Patients unable to undergo MRI with gadolinium-based contrast for standard clinical reasons which include: - Cardiac pacemaker, aneurysm clip, cochlear implants, Intra Uterine Device (IUD), shrapnel, neurostimulators, defibrillator, artificial heart valve, or history of metal fragments in eyes. - Pregnancy - Body size too large for closed MRI - Known hepatic fibrosis. - Claustrophobia - Contraindication to MR contrast agents: eGFR (epidermal growth factor receptor) < 30 by the Cockcroft- Gault formula if > 60 years old or with chronic renal disease - Anaphylactic allergy to gadolinium |
Country | Name | City | State |
---|---|---|---|
United States | Yale University | New Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Yale University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Regrowing Tumor Rate from Radiation Effect | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01913067 -
Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC
|
Phase 2 | |
Completed |
NCT02662725 -
Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases
|
Phase 2 | |
Completed |
NCT00406835 -
Prospective Randomized Trial Between WBRT Plus SRS Versus SRS Alone for 1-4 Brain Metastases
|
Phase 3 | |
Completed |
NCT01724801 -
Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer
|
Phase 3 | |
Completed |
NCT00219297 -
Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT02328300 -
FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions
|
||
Terminated |
NCT01324635 -
Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors
|
Phase 1 | |
Terminated |
NCT01894633 -
Study of Whole-brain Irradiation With Chloroquine for Brain Metastases
|
Phase 2 | |
Recruiting |
NCT02681549 -
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT02279992 -
Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases
|
Early Phase 1 | |
Completed |
NCT02913534 -
Hypofractionated Stereotactic Radiation Therapy of Brain Metastases: Evaluation of Whole-brain Radiotherapy
|
N/A | |
Completed |
NCT01942980 -
Evaluation of the Efficacy of Hippocampal Avoidance on the Cognitive Toxicity of Whole-Brain Radiation Therapy After Surgical Resection of Single Brain Metastasis of Breast Cancer
|
Phase 3 | |
Terminated |
NCT01363557 -
Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis
|
N/A | |
Active, not recruiting |
NCT05102747 -
Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation.
|
N/A | |
Recruiting |
NCT01891708 -
VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer
|
N/A | |
Completed |
NCT01508221 -
Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis
|
Phase 2 | |
Completed |
NCT00587964 -
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
|
Phase 2 | |
Not yet recruiting |
NCT06462079 -
Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases
|
Phase 2 | |
Not yet recruiting |
NCT02832635 -
A Clinical Trial on Whole-brain Radiotherapy With Temozolomide Concurrent Chemotherapy or Avoidance of Hippocampus for Patients of Brain Metastases
|
Phase 2 | |
Completed |
NCT01395407 -
Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Brain Metastases
|
Phase 1 |